The Experts below are selected from a list of 29349 Experts worldwide ranked by ideXlab platform
Mingjun Zhang - One of the best experts on this subject based on the ideXlab platform.
-
a bioinspired alginate gum arabic hydrogel with micro nanoscale structures for controlled drug release in Chronic Wound healing
ACS Applied Materials & Interfaces, 2017Co-Authors: Mi Li, Haichang Li, Xiangguang Li, Zihui Xu, Mingjun ZhangAbstract:Biopolymeric hydrogels have drawn increasing research interest in biomaterials due to their tunable physical and chemical properties for both creating bioactive cellular microenvironment and serving as sustainable therapeutic reagents. Inspired by a naturally occurring hydrogel secreted from the carnivorous Sundew plant for trapping insects, here we have developed a bioinspired hydrogel to deliver mitsugumin 53 (MG53), an important protein in cell membrane repair, for Chronic Wound healing. Both chemical compositions and micro-/nanomorphological properties inherent from the natural Sundew hydrogel were mimicked using sodium alginate and gum arabic with calcium ion-mediated cross-linking. On the basis of atomic force microscopy (AFM) force measurements, an optimal sticky hydrogel scaffold was obtained through orthogonal experimental design. Imaging and mechanical analysis showed the distinct correlation between structural morphology, adhesion characteristics, and mechanical properties of the Sundew-inspire...
-
a bioinspired alginate gum arabic hydrogel with micro nanoscale structures for controlled drug release in Chronic Wound healing
ACS Applied Materials & Interfaces, 2017Co-Authors: Hua Zhu, Lianqing Liu, Mingjun ZhangAbstract:Biopolymeric hydrogels have drawn increasing research interest in biomaterials due to their tunable physical and chemical properties for both creating bioactive cellular microenvironment and serving as sustainable therapeutic reagents. Inspired by a naturally occurring hydrogel secreted from the carnivorous Sundew plant for trapping insects, here we have developed a bioinspired hydrogel to deliver mitsugumin 53 (MG53), an important protein in cell membrane repair, for Chronic Wound healing. Both chemical compositions and micro-/nanomorphological properties inherent from the natural Sundew hydrogel were mimicked using sodium alginate and gum arabic with calcium ion-mediated cross-linking. On the basis of atomic force microscopy (AFM) force measurements, an optimal sticky hydrogel scaffold was obtained through orthogonal experimental design. Imaging and mechanical analysis showed the distinct correlation between structural morphology, adhesion characteristics, and mechanical properties of the Sundew-inspired hydrogel. Combined characterization and biochemistry techniques were utilized to uncover the underlying molecular composition involved in the interactions between hydrogel and protein. In vitro drug release experiments confirmed that the Sundew-inspired hydrogel had a biphasic-kinetics release, which can facilitate both fast delivery of MG53 for improving the reepithelization process of the Wounds and sustained release of the protein for treating Chronic Wounds. In vivo experiments showed that the Sundew-inspired hydrogel encapsulating with rhMG53 could facilitate dermal Wound healing in mouse model. Together, these studies confirmed that the Sundew-inspired hydrogel has both tunable micro-/nanostructures and physicochemical properties, which enable it as a delivery vehicle for Chronic Wounding healing. The research may provide a new way to develop biocompatible and tunable biomaterials for sustainable drug release to meet the needs of biological activities.
David Thomas - One of the best experts on this subject based on the ideXlab platform.
-
bioresponsive dextrin rhegf conjugates in vitro evaluation in models relevant to its proposed use as a treatment for Chronic Wounds
Molecular Pharmaceutics, 2010Co-Authors: Joseph Hardwicke, Ryan Moseley, Keith Harding, Philip Stephens, Ruth Duncan, David ThomasAbstract:We recently developed a bioresponsive dextrin-recombinant human epidermal growth factor (rhEGF) conjugate as a polymer therapeutic with potential for use in the promotion of tissue repair. The aim of these studies was to use patient-derived Wound fluid and fibroblasts to evaluate its potential for further development as a treatment for Chronic Wounds, such as venous leg ulceration, a growing clinical challenge in the aging population. First, the levels of EGF (ELISA assay), alpha-amylase and elastase (enzyme assays) were measured in patient-derived acute and Chronic Wound fluid. EGF was detected in acute, but not in Chronic Wound fluid. alpha-Amylase concentrations were higher in acute (188 IU/L), compared to Chronic Wound fluid (52 IU/L), but both were in the range of human serum levels. Although elastase was present in Chronic Wound fluid (2.1 +/- 1.2 RFU/min), none was detected in acute Wound fluid. Dextrin-rhEGF incubation in Chronic Wound fluid led to endogenous a-amylase-mediated release of rhEGF (ELISA) that was maximal at 48 h. When the migration of HaCaT keratinocytes and of human fibroblasts (isolated from patient-matched, normal skin and Chronic dermal Wounds) was studied in vitro using the scratch Wound assay, enhanced cell migration was observed in response to both free rhEGF and a-amylase-activated dextrin-rhEGF conjugate compared to controls. In addition, fibroblasts displayed increased proliferation (normal dermal fibroblasts similar to 160%; Chronic Wound fibroblasts similar to 140%) following incubation (72 h) with dextrin-rhEGF that had been exposed to physiological levels of alpha-amylase (93 IU/L). These results suggest further preclinical in vivo evaluation of dextrin-rhEGF is warranted to determine whether conjugate pharmacokinetics and rhEGF liberation into such a complex and aggressive environment can still lead to bioactivity.
-
an in vitro model of Chronic Wound biofilms to test Wound dressings and assess antimicrobial susceptibilities
Journal of Antimicrobial Chemotherapy, 2010Co-Authors: Katja E Hill, Keith Harding, Sladjana Malic, Ruth Mckee, Tracy Rennison, David Wynne Williams, David ThomasAbstract:Objectives: The targeted disruption of biofilms in Chronic Wounds is an important treatment strategy and the subject of intense research. In the present study, an in vitro model of Chronic Wound biofilms was developed to assess the efficacy of antimicrobial treatments for use in the Wound environment. Methods: Using Chronic Wound isolates, assays of bacterial coaggregation established that aerobic and anaerobic Wound bacteria were able to coaggregate and form biofilms. A constant depth film fermenter (CDFF) was used to develop Wound biofilms in vitro, which were analysed using light microscopy and scanning electron microscopy. The susceptibility of bacteria within these biofilms was examined in response to the most frequently prescribed ‘Chronic Wound’ antibiotics and a series of iodine- and silver-containing commercial antimicrobial products and lactoferrin. Results: Defined biofilms were rapidly established within 1‐2 days. Antibiotic treatment demonstrated that mixed Pseudomonas and Staphylococcus biofilms were not affected by ciprofloxacin (5 mg/L) or flucloxacillin (15 mg/L), even at concentrations equivalent to twice the observed peak serum levels. The results contrasted with the ability of povidone‐iodine (1%) to disrupt the Wound biofilm; an effect that was particularly pronounced in the dressing testing where iodine-based dressings completely disrupted established 7 day biofilms. In contrast, only two of six silver-containing dressings exhibited any effect on 3 day biofilms, with no effect on 7 day biofilms. Conclusions: This Wound model emphasizes the potential role of the biofilm phenotype in the observed resistance to antibiotic therapies that may occur in Chronic Wounds in vivo.
-
comparison of oxidative stress biomarker profiles between acute and Chronic Wound environments
Wound Repair and Regeneration, 2004Co-Authors: Ryan Moseley, Joanna Ruth Hilton, Rachel J Waddington, Keith Harding, Philip Stephens, David ThomasAbstract:Increasing evidence implicates excessive reactive oxygen species (ROS) generation and ROS-derived degradation products in the pathogenesis of many skin diseases. While numerous attempts have been made to identify prognostic biomarkers of Wound healing in skin, these have met with limited success. This study examined the profiles of various oxidative stress biomarkers, namely total protein carbonyl content (from protein oxidation), malondialdehyde content (from lipid peroxidation), and the total antioxidant capacities, in acute Wound fluid (n= 10) and Chronic Wound fluid (n= 12), using a rapid, noninvasive collection technique. Protein carbonyl content was quantified spectrophotometrically and by sodium dodecyl sulfate-polyacrylamide gel electrophoresis/Western blotting, following 2,4-dinitrophenylhydrazine derivitization. Malondialdehyde levels were similarly quantified, following N-methyl-2-phenylindole derivitization. Total antioxidant capacity was determined via Wound fluid inhibition of cytochrome C reduction by a superoxide radical flux. Acute Wound fluid contained higher protein carbonyl content than Chronic Wound fluid, particularly evident following sodium dodecyl sulfate-polyacrylamide gel electrophoresis/Western blot analysis under nonreducing and reducing conditions (p 0.1) in malondialdehyde levels or total antioxidant capacities were determined between acute and Chronic Wound fluids, although Chronic Wound fluid exhibited significantly higher total antioxidant capacities (p < 0.005), accounting for variations in Wound fluid protein content. These findings suggest an adaptation in the antioxidant profiles of Chronic Wound fluid to counteract the loss of consumed antioxidants in the Chronic Wound environment. This study highlights the roles of ROS/antioxidants in skin Wound healing, their possible involvement in Chronic Wounds and the potential value of ROS-induced biomarkers in Wound healing prognosis.
Keith Harding - One of the best experts on this subject based on the ideXlab platform.
-
bioresponsive dextrin rhegf conjugates in vitro evaluation in models relevant to its proposed use as a treatment for Chronic Wounds
Molecular Pharmaceutics, 2010Co-Authors: Joseph Hardwicke, Ryan Moseley, Keith Harding, Philip Stephens, Ruth Duncan, D W P ThomasAbstract:We recently developed a bioresponsive dextrin-recombinant human epidermal growth factor (rhEGF) conjugate as a polymer therapeutic with potential for use in the promotion of tissue repair. The aim of these studies was to use patient-derived Wound fluid and fibroblasts to evaluate its potential for further development as a treatment for Chronic Wounds, such as venous leg ulceration, a growing clinical challenge in the aging population. First, the levels of EGF (ELISA assay), α-amylase and elastase (enzyme assays) were measured in patient-derived acute and Chronic Wound fluid. EGF was detected in acute, but not in Chronic Wound fluid. α-Amylase concentrations were higher in acute (188 IU/L), compared to Chronic Wound fluid (52 IU/L), but both were in the range of human serum levels. Although elastase was present in Chronic Wound fluid (2.1 ± 1.2 RFU/min), none was detected in acute Wound fluid. Dextrin−rhEGF incubation in Chronic Wound fluid led to endogenous α-amylase-mediated release of rhEGF (ELISA) that...
-
bioresponsive dextrin rhegf conjugates in vitro evaluation in models relevant to its proposed use as a treatment for Chronic Wounds
Molecular Pharmaceutics, 2010Co-Authors: Joseph Hardwicke, Ryan Moseley, Keith Harding, Philip Stephens, Ruth Duncan, David ThomasAbstract:We recently developed a bioresponsive dextrin-recombinant human epidermal growth factor (rhEGF) conjugate as a polymer therapeutic with potential for use in the promotion of tissue repair. The aim of these studies was to use patient-derived Wound fluid and fibroblasts to evaluate its potential for further development as a treatment for Chronic Wounds, such as venous leg ulceration, a growing clinical challenge in the aging population. First, the levels of EGF (ELISA assay), alpha-amylase and elastase (enzyme assays) were measured in patient-derived acute and Chronic Wound fluid. EGF was detected in acute, but not in Chronic Wound fluid. alpha-Amylase concentrations were higher in acute (188 IU/L), compared to Chronic Wound fluid (52 IU/L), but both were in the range of human serum levels. Although elastase was present in Chronic Wound fluid (2.1 +/- 1.2 RFU/min), none was detected in acute Wound fluid. Dextrin-rhEGF incubation in Chronic Wound fluid led to endogenous a-amylase-mediated release of rhEGF (ELISA) that was maximal at 48 h. When the migration of HaCaT keratinocytes and of human fibroblasts (isolated from patient-matched, normal skin and Chronic dermal Wounds) was studied in vitro using the scratch Wound assay, enhanced cell migration was observed in response to both free rhEGF and a-amylase-activated dextrin-rhEGF conjugate compared to controls. In addition, fibroblasts displayed increased proliferation (normal dermal fibroblasts similar to 160%; Chronic Wound fibroblasts similar to 140%) following incubation (72 h) with dextrin-rhEGF that had been exposed to physiological levels of alpha-amylase (93 IU/L). These results suggest further preclinical in vivo evaluation of dextrin-rhEGF is warranted to determine whether conjugate pharmacokinetics and rhEGF liberation into such a complex and aggressive environment can still lead to bioactivity.
-
an in vitro model of Chronic Wound biofilms to test Wound dressings and assess antimicrobial susceptibilities
Journal of Antimicrobial Chemotherapy, 2010Co-Authors: Katja E Hill, Keith Harding, Sladjana Malic, Ruth Mckee, Tracy Rennison, David Wynne Williams, David ThomasAbstract:Objectives: The targeted disruption of biofilms in Chronic Wounds is an important treatment strategy and the subject of intense research. In the present study, an in vitro model of Chronic Wound biofilms was developed to assess the efficacy of antimicrobial treatments for use in the Wound environment. Methods: Using Chronic Wound isolates, assays of bacterial coaggregation established that aerobic and anaerobic Wound bacteria were able to coaggregate and form biofilms. A constant depth film fermenter (CDFF) was used to develop Wound biofilms in vitro, which were analysed using light microscopy and scanning electron microscopy. The susceptibility of bacteria within these biofilms was examined in response to the most frequently prescribed ‘Chronic Wound’ antibiotics and a series of iodine- and silver-containing commercial antimicrobial products and lactoferrin. Results: Defined biofilms were rapidly established within 1‐2 days. Antibiotic treatment demonstrated that mixed Pseudomonas and Staphylococcus biofilms were not affected by ciprofloxacin (5 mg/L) or flucloxacillin (15 mg/L), even at concentrations equivalent to twice the observed peak serum levels. The results contrasted with the ability of povidone‐iodine (1%) to disrupt the Wound biofilm; an effect that was particularly pronounced in the dressing testing where iodine-based dressings completely disrupted established 7 day biofilms. In contrast, only two of six silver-containing dressings exhibited any effect on 3 day biofilms, with no effect on 7 day biofilms. Conclusions: This Wound model emphasizes the potential role of the biofilm phenotype in the observed resistance to antibiotic therapies that may occur in Chronic Wounds in vivo.
-
comparison of oxidative stress biomarker profiles between acute and Chronic Wound environments
Wound Repair and Regeneration, 2004Co-Authors: Ryan Moseley, Joanna Ruth Hilton, Rachel J Waddington, Keith Harding, Philip Stephens, David ThomasAbstract:Increasing evidence implicates excessive reactive oxygen species (ROS) generation and ROS-derived degradation products in the pathogenesis of many skin diseases. While numerous attempts have been made to identify prognostic biomarkers of Wound healing in skin, these have met with limited success. This study examined the profiles of various oxidative stress biomarkers, namely total protein carbonyl content (from protein oxidation), malondialdehyde content (from lipid peroxidation), and the total antioxidant capacities, in acute Wound fluid (n= 10) and Chronic Wound fluid (n= 12), using a rapid, noninvasive collection technique. Protein carbonyl content was quantified spectrophotometrically and by sodium dodecyl sulfate-polyacrylamide gel electrophoresis/Western blotting, following 2,4-dinitrophenylhydrazine derivitization. Malondialdehyde levels were similarly quantified, following N-methyl-2-phenylindole derivitization. Total antioxidant capacity was determined via Wound fluid inhibition of cytochrome C reduction by a superoxide radical flux. Acute Wound fluid contained higher protein carbonyl content than Chronic Wound fluid, particularly evident following sodium dodecyl sulfate-polyacrylamide gel electrophoresis/Western blot analysis under nonreducing and reducing conditions (p 0.1) in malondialdehyde levels or total antioxidant capacities were determined between acute and Chronic Wound fluids, although Chronic Wound fluid exhibited significantly higher total antioxidant capacities (p < 0.005), accounting for variations in Wound fluid protein content. These findings suggest an adaptation in the antioxidant profiles of Chronic Wound fluid to counteract the loss of consumed antioxidants in the Chronic Wound environment. This study highlights the roles of ROS/antioxidants in skin Wound healing, their possible involvement in Chronic Wounds and the potential value of ROS-induced biomarkers in Wound healing prognosis.
Ryan Moseley - One of the best experts on this subject based on the ideXlab platform.
-
bioresponsive dextrin rhegf conjugates in vitro evaluation in models relevant to its proposed use as a treatment for Chronic Wounds
Molecular Pharmaceutics, 2010Co-Authors: Joseph Hardwicke, Ryan Moseley, Keith Harding, Philip Stephens, Ruth Duncan, David ThomasAbstract:We recently developed a bioresponsive dextrin-recombinant human epidermal growth factor (rhEGF) conjugate as a polymer therapeutic with potential for use in the promotion of tissue repair. The aim of these studies was to use patient-derived Wound fluid and fibroblasts to evaluate its potential for further development as a treatment for Chronic Wounds, such as venous leg ulceration, a growing clinical challenge in the aging population. First, the levels of EGF (ELISA assay), alpha-amylase and elastase (enzyme assays) were measured in patient-derived acute and Chronic Wound fluid. EGF was detected in acute, but not in Chronic Wound fluid. alpha-Amylase concentrations were higher in acute (188 IU/L), compared to Chronic Wound fluid (52 IU/L), but both were in the range of human serum levels. Although elastase was present in Chronic Wound fluid (2.1 +/- 1.2 RFU/min), none was detected in acute Wound fluid. Dextrin-rhEGF incubation in Chronic Wound fluid led to endogenous a-amylase-mediated release of rhEGF (ELISA) that was maximal at 48 h. When the migration of HaCaT keratinocytes and of human fibroblasts (isolated from patient-matched, normal skin and Chronic dermal Wounds) was studied in vitro using the scratch Wound assay, enhanced cell migration was observed in response to both free rhEGF and a-amylase-activated dextrin-rhEGF conjugate compared to controls. In addition, fibroblasts displayed increased proliferation (normal dermal fibroblasts similar to 160%; Chronic Wound fibroblasts similar to 140%) following incubation (72 h) with dextrin-rhEGF that had been exposed to physiological levels of alpha-amylase (93 IU/L). These results suggest further preclinical in vivo evaluation of dextrin-rhEGF is warranted to determine whether conjugate pharmacokinetics and rhEGF liberation into such a complex and aggressive environment can still lead to bioactivity.
-
bioresponsive dextrin rhegf conjugates in vitro evaluation in models relevant to its proposed use as a treatment for Chronic Wounds
Molecular Pharmaceutics, 2010Co-Authors: Joseph Hardwicke, Ryan Moseley, Keith Harding, Philip Stephens, Ruth Duncan, D W P ThomasAbstract:We recently developed a bioresponsive dextrin-recombinant human epidermal growth factor (rhEGF) conjugate as a polymer therapeutic with potential for use in the promotion of tissue repair. The aim of these studies was to use patient-derived Wound fluid and fibroblasts to evaluate its potential for further development as a treatment for Chronic Wounds, such as venous leg ulceration, a growing clinical challenge in the aging population. First, the levels of EGF (ELISA assay), α-amylase and elastase (enzyme assays) were measured in patient-derived acute and Chronic Wound fluid. EGF was detected in acute, but not in Chronic Wound fluid. α-Amylase concentrations were higher in acute (188 IU/L), compared to Chronic Wound fluid (52 IU/L), but both were in the range of human serum levels. Although elastase was present in Chronic Wound fluid (2.1 ± 1.2 RFU/min), none was detected in acute Wound fluid. Dextrin−rhEGF incubation in Chronic Wound fluid led to endogenous α-amylase-mediated release of rhEGF (ELISA) that...
-
comparison of oxidative stress biomarker profiles between acute and Chronic Wound environments
Wound Repair and Regeneration, 2004Co-Authors: Ryan Moseley, Joanna Ruth Hilton, Rachel J Waddington, Keith Harding, Philip Stephens, David ThomasAbstract:Increasing evidence implicates excessive reactive oxygen species (ROS) generation and ROS-derived degradation products in the pathogenesis of many skin diseases. While numerous attempts have been made to identify prognostic biomarkers of Wound healing in skin, these have met with limited success. This study examined the profiles of various oxidative stress biomarkers, namely total protein carbonyl content (from protein oxidation), malondialdehyde content (from lipid peroxidation), and the total antioxidant capacities, in acute Wound fluid (n= 10) and Chronic Wound fluid (n= 12), using a rapid, noninvasive collection technique. Protein carbonyl content was quantified spectrophotometrically and by sodium dodecyl sulfate-polyacrylamide gel electrophoresis/Western blotting, following 2,4-dinitrophenylhydrazine derivitization. Malondialdehyde levels were similarly quantified, following N-methyl-2-phenylindole derivitization. Total antioxidant capacity was determined via Wound fluid inhibition of cytochrome C reduction by a superoxide radical flux. Acute Wound fluid contained higher protein carbonyl content than Chronic Wound fluid, particularly evident following sodium dodecyl sulfate-polyacrylamide gel electrophoresis/Western blot analysis under nonreducing and reducing conditions (p 0.1) in malondialdehyde levels or total antioxidant capacities were determined between acute and Chronic Wound fluids, although Chronic Wound fluid exhibited significantly higher total antioxidant capacities (p < 0.005), accounting for variations in Wound fluid protein content. These findings suggest an adaptation in the antioxidant profiles of Chronic Wound fluid to counteract the loss of consumed antioxidants in the Chronic Wound environment. This study highlights the roles of ROS/antioxidants in skin Wound healing, their possible involvement in Chronic Wounds and the potential value of ROS-induced biomarkers in Wound healing prognosis.
Philip Stephens - One of the best experts on this subject based on the ideXlab platform.
-
bioresponsive dextrin rhegf conjugates in vitro evaluation in models relevant to its proposed use as a treatment for Chronic Wounds
Molecular Pharmaceutics, 2010Co-Authors: Joseph Hardwicke, Ryan Moseley, Keith Harding, Philip Stephens, Ruth Duncan, David ThomasAbstract:We recently developed a bioresponsive dextrin-recombinant human epidermal growth factor (rhEGF) conjugate as a polymer therapeutic with potential for use in the promotion of tissue repair. The aim of these studies was to use patient-derived Wound fluid and fibroblasts to evaluate its potential for further development as a treatment for Chronic Wounds, such as venous leg ulceration, a growing clinical challenge in the aging population. First, the levels of EGF (ELISA assay), alpha-amylase and elastase (enzyme assays) were measured in patient-derived acute and Chronic Wound fluid. EGF was detected in acute, but not in Chronic Wound fluid. alpha-Amylase concentrations were higher in acute (188 IU/L), compared to Chronic Wound fluid (52 IU/L), but both were in the range of human serum levels. Although elastase was present in Chronic Wound fluid (2.1 +/- 1.2 RFU/min), none was detected in acute Wound fluid. Dextrin-rhEGF incubation in Chronic Wound fluid led to endogenous a-amylase-mediated release of rhEGF (ELISA) that was maximal at 48 h. When the migration of HaCaT keratinocytes and of human fibroblasts (isolated from patient-matched, normal skin and Chronic dermal Wounds) was studied in vitro using the scratch Wound assay, enhanced cell migration was observed in response to both free rhEGF and a-amylase-activated dextrin-rhEGF conjugate compared to controls. In addition, fibroblasts displayed increased proliferation (normal dermal fibroblasts similar to 160%; Chronic Wound fibroblasts similar to 140%) following incubation (72 h) with dextrin-rhEGF that had been exposed to physiological levels of alpha-amylase (93 IU/L). These results suggest further preclinical in vivo evaluation of dextrin-rhEGF is warranted to determine whether conjugate pharmacokinetics and rhEGF liberation into such a complex and aggressive environment can still lead to bioactivity.
-
bioresponsive dextrin rhegf conjugates in vitro evaluation in models relevant to its proposed use as a treatment for Chronic Wounds
Molecular Pharmaceutics, 2010Co-Authors: Joseph Hardwicke, Ryan Moseley, Keith Harding, Philip Stephens, Ruth Duncan, D W P ThomasAbstract:We recently developed a bioresponsive dextrin-recombinant human epidermal growth factor (rhEGF) conjugate as a polymer therapeutic with potential for use in the promotion of tissue repair. The aim of these studies was to use patient-derived Wound fluid and fibroblasts to evaluate its potential for further development as a treatment for Chronic Wounds, such as venous leg ulceration, a growing clinical challenge in the aging population. First, the levels of EGF (ELISA assay), α-amylase and elastase (enzyme assays) were measured in patient-derived acute and Chronic Wound fluid. EGF was detected in acute, but not in Chronic Wound fluid. α-Amylase concentrations were higher in acute (188 IU/L), compared to Chronic Wound fluid (52 IU/L), but both were in the range of human serum levels. Although elastase was present in Chronic Wound fluid (2.1 ± 1.2 RFU/min), none was detected in acute Wound fluid. Dextrin−rhEGF incubation in Chronic Wound fluid led to endogenous α-amylase-mediated release of rhEGF (ELISA) that...
-
comparison of oxidative stress biomarker profiles between acute and Chronic Wound environments
Wound Repair and Regeneration, 2004Co-Authors: Ryan Moseley, Joanna Ruth Hilton, Rachel J Waddington, Keith Harding, Philip Stephens, David ThomasAbstract:Increasing evidence implicates excessive reactive oxygen species (ROS) generation and ROS-derived degradation products in the pathogenesis of many skin diseases. While numerous attempts have been made to identify prognostic biomarkers of Wound healing in skin, these have met with limited success. This study examined the profiles of various oxidative stress biomarkers, namely total protein carbonyl content (from protein oxidation), malondialdehyde content (from lipid peroxidation), and the total antioxidant capacities, in acute Wound fluid (n= 10) and Chronic Wound fluid (n= 12), using a rapid, noninvasive collection technique. Protein carbonyl content was quantified spectrophotometrically and by sodium dodecyl sulfate-polyacrylamide gel electrophoresis/Western blotting, following 2,4-dinitrophenylhydrazine derivitization. Malondialdehyde levels were similarly quantified, following N-methyl-2-phenylindole derivitization. Total antioxidant capacity was determined via Wound fluid inhibition of cytochrome C reduction by a superoxide radical flux. Acute Wound fluid contained higher protein carbonyl content than Chronic Wound fluid, particularly evident following sodium dodecyl sulfate-polyacrylamide gel electrophoresis/Western blot analysis under nonreducing and reducing conditions (p 0.1) in malondialdehyde levels or total antioxidant capacities were determined between acute and Chronic Wound fluids, although Chronic Wound fluid exhibited significantly higher total antioxidant capacities (p < 0.005), accounting for variations in Wound fluid protein content. These findings suggest an adaptation in the antioxidant profiles of Chronic Wound fluid to counteract the loss of consumed antioxidants in the Chronic Wound environment. This study highlights the roles of ROS/antioxidants in skin Wound healing, their possible involvement in Chronic Wounds and the potential value of ROS-induced biomarkers in Wound healing prognosis.
